Anadis (ANX)

Shares / Stock Code

ANX

Stock Exchange / Sharemarket

ax

Anadis (ANX) is a bio-pharmaceutical research and development company. The company's principal activities incorporate the use of polyclonal antibodies for the treatment and prevention of key diseases. Its products offer immediate-acting, surface-based immune protection, which are considered to speed up the repair of damaged gastrointestinal mucosa, damaged due to disease, toxins or radiation, by lessening the bodies own local inflammatory processes that contribute to such damage. Anadis listed on ASX on April 30, 1999. The company's key product is Travelan, which is used for the treatment of Travellers’ Diarrhoea. Anadis is focused on the investment and production of antibodies for the prevention and possible treatment for hospital and community acquired nosocomial infections, especially Clostridium difficile and Golden Staph/ Staphylococcus aureus and methicillin susceptible. Anadis has also been involved in the production of antibodies against Enterovirus (EV) 71, a polio-like epidemic. The product has formulation as EVProtec with the key ingredient being antibodies against EV-71. The product is produced in powder form to be packaged in sachets. In February 2006, the Company declared the manufacturing of bulk antibodies against Ricin and Botulism for the Department of Defence to provide diagnostic reagents to the Australian Public Health Network.

The company's manufacturing technology is highly scalable resulting in the cost effective production, commercialization and regulatory pathway for a range of immunotherapeutics. Indication consists of influenza, Mucositis, IBD/ IBS, Traveller's Diarrhea, C.Difficile, and Anthrax and other bioagents containment. ANX is also focused in forming alliances with food manufacturers to have its active compounds in their healthy food.

Anadis History

Anadis (ANX) was listed on the ASX in April 1999. The company has established numerous strategic collaborations within Australia, Taiwan and North America. ANX also has also alliances with the health research community in Melbourne and the dairy industry in Australia.